HistoryThis section has been translated automatically.
DefinitionThis section has been translated automatically.
You might also be interested in
Occurrence/EpidemiologyThis section has been translated automatically.
- More than 10,000 patients are affected worldwide. The disease occurs mainly in the Mediterranean region (e.g. Armenian, Turkish, Arab and Jewish population). Due to immigration, however, this clinical picture is also of differential diagnostic importance in Western countries.
- Depending on the study and the collective, the frequency of heterozygous gene carriers is 1:26 to 1:52. The disease manifests itself when a homozygous (both alleles carry the same mutation) or compound heterozygous (both alleles carry different mutations) status is present. For heterozygous parents, this means that the risk of producing a homozygous or compound heterozygous (diseased) child is 25%.
EtiopathogenesisThis section has been translated automatically.
ManifestationThis section has been translated automatically.
Clinical featuresThis section has been translated automatically.
- Phenotype 1: Beginning with fever attacks.
- Phenotype 2: Amyloidosis as the first manifestation.
LaboratoryThis section has been translated automatically.
ESR elevated, rarely leukocytosis. Elevated serum amyloid A is only observed in manifest amyloidosis, which is a complication of FMF and does not serve as the primary diagnosis. Regular (collection!) urine testsshould therefore be an integral part of patient care.
DiagnosisThis section has been translated automatically.
Differential diagnosisThis section has been translated automatically.
Complication(s)This section has been translated automatically.
- Consequential damage such as kidney failure due to systemic amyloidosis.
- Infertility in about 30% of women with the disease. 20-30% of pregnancies in patients end in premature abortion.
TherapyThis section has been translated automatically.
LiteratureThis section has been translated automatically.
- Aldea A et al (2004) A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: An unusual familial Mediterranean fever phenotype or another MEFV-associated periodic inflammatory disorder? On J Med Genet 124A: 67-73
- Gershoni-Baruch R et al (2003) Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schonlein purpura. J Pediatr 143: 658-661
- Janeway TC, Mosenthal HO (1908) An unusual paroxysmal syndrome, probably allied to recurrent vomiting, with a study of the nitrogen metabolism. Trans Ass Am Phys 23: 504-518
- Osler W (1895) On the visceral manifestations of erythema multiforme. On J Med Sci 110: 629
- Panossian A et al (2003) Plasma nitric oxide level in familial Mediterranean fever and its modulations by Immuno-Guard. Nitric oxide 9: 103-110
- Sayarlioglu M et al (2003) Colchicine-induced myopathy in a teenager with familial Mediterranean fever. Ann Pharmacother 37: 1821-1824
- Timmann C et al (2003) Familial Mediterranean fever with amyloidosis associated with novel exon 2 mutation (S1791) of the MEFV gene. Blood Cells Mol Dis 31: 320-323
Incoming links (7)Amyloid-a; Dermatitis-arthritis syndromes; Familial cold urticaria; Familial mediterranean fever; Fmf; Papa syndrome; Pfapa syndrome;
Outgoing links (10)Amyloidosis systemic (overview); Colchicine; Familial cold urticaria; Fever syndromes, hereditary, periodic (overview); Hyper-igd syndrome; Muckle-wells syndrome; Pfapa syndrome; Tumor necrosis factor receptor associated periodic syndrome; Urticaria (overview); Urticaria vasculitis;
Please ask your physician for a reliable diagnosis. This website is only meant as a reference.